RetinaLyze®

An Artificial Intelligence tool for rapid retinal investigation, identifying diseases like:

  • Glaucoma,
  • Diabetic Retinopathy,
  • Macular Degeneration

A powerful prevention tool and aid for medical professionals.

Precision and Speed: our AI technology analyzes images of the optic nerve, detecting signs of diseases with proven effectiveness

Without and With Retinalyze Pathology Detection

Detects eye pathologies in 3 quick steps:

With RetinaLyze®, it is possible to:

  • Reduce diagnosis time from hours to minutes
  • Decrease the financial costs involved in diagnosis

  • Support medical diagnosis with efficient and secure data
  • Expand access and availability to ophthalmic care

  • Promote digital health to the entire population

Retinalyze positions itself as an essential solution for enhancing

clinical efficiency and safeguarding eye health on a large scale.

0
Integration with over 20 Retinographs, including national brands
0Mi
Tested on over 6.5 million patients
0
Marketed in 35 countries worldwide
Efficient

The algorithm classifies patients into two groups: those who need medical follow-up and those who do not. The ophthalmologists on the team can then focus on diagnosing and treating patients who really need their time. This way, RetinaLyze®️ reduces up to 60% of the manual workload.

Fast

RetinaLyze® provides instant results, through automated screening for signs of diabetic retinopathy, age-related macular degeneration, and glaucoma. There is also the possibility of integration with telemedicine platforms, allowing the sharing of images with doctors for diagnosis.

Secure

Security is very important to us. All communication is encrypted. An intermediary will not be able to view or edit images, results, or patient information. RetinaLyze® is registered with ANVISA and has CE marking. Data travels at the highest level of encryption currently available.

Easy to Use

RetinaLyze® has been developed for easy use and learning by doctors and health professionals. The system can be easily adapted to meet the needs of a single clinic, a large network of ophthalmologists or hospitals, as well as for screening in prevention campaigns promoted by health professionals.

Global Impact: Case Studies

RetinaLyze® is backed by global scientific studies, demonstrating its accuracy and reliability in diagnosing eye diseases.

In Brazil, researchers from UNIFESP and UNICAMP validated its effectiveness in early identification of diabetic retinopathy, significantly contributing to the prevention of blindness.

Internationally, studies conducted in Europe and Asia confirm its utility in various clinical settings, establishing RetinaLyze® as an indispensable tool for ophthalmologists and health professionals.

Efficient

O algoritmo classifica os pacientes em dois grupos: os que precisam de acompanhamento médico e os que não precisam. Os oftalmologistas da equipe podem então se concentrar em diagnosticar e tratar pacientes que realmente precisam de seu tempo. Desta forma, RetinaLyze® reduz até 60% da carga de trabalho manual.

Fast

RetinaLyze® provides instant results, through automated screening for signs of diabetic retinopathy, age-related macular degeneration, and glaucoma. There is also the possibility of integration with telemedicine platforms, allowing the sharing of images with doctors for diagnosis.

Secure

Security is very important to us. All communication is encrypted. An intermediary will not be able to view or edit images, results, or patient information. RetinaLyze® is registered with ANVISA and has CE marking. Data travels at the highest level of encryption currently available.

Easy to Use

RetinaLyze® has been developed for easy use and learning by doctors and health professionals. The system can be easily adapted to meet the needs of a single clinic, a large network of ophthalmologists or hospitals, as well as for screening in prevention campaigns promoted by health professionals.

Global Impact: Case Studies

RetinaLyze® is backed by global scientific studies, demonstrating its accuracy and reliability in diagnosing eye diseases.

In Brazil, researchers from UNIFESP and UNICAMP validated its effectiveness in early identification of diabetic retinopathy, significantly contributing to the prevention of blindness.

Internationally, studies conducted in Europe and Asia confirm its utility in various clinical settings, establishing RetinaLyze® as an indispensable tool for ophthalmologists and health professionals.

Pathologies:

Glaucoma
The leading cause of preventable blindness worldwide.

About 2.5 millions people over 40 years old are affected in Brazil.

Diabetic Retinopathy,
One of the main causes of blindness in working-age people (16 – 64 years old).

About 90%s of cases could be prevented with early diagnosis and appropriate treatment.

AMD
A multifactorial disease, the progressive damage to the macula is the main cause of legal blindness in individuals over 50 years old.
Source: Mendez-Hernandez et. al 2016, Hernández, M.G. (2018)

ANVISA Library

Retinalyze System

Software médico de investigação da retina
Fabricante: Retinalyze System A/S, Bernstorffsvej 20, 2900 Hellerup – Dinamarca
Detentor da notificação: Ávita Care Importação e Distribuição de Produtos LTDA.

Ver instruções de uso

RESOLUÇÃO-RE Nº 698, DE 22 DE FEVEREIRO DE 2024

ÁVITA CARE IMPORTAÇÃO E DISTRIBUIÇÃO DE PRODUTOS LTDA. / 31.203.582/0001-37
RetinaLyze System – 25351.917968/2024-01 / 81769290002
80272 – EQUIPAMENTO – Notificação de Software Médico Classe I ou II / 0052577244

Ler publicação

Nome Comercial: Retinalyze System
Modelo: RETINALYZE System
Nome técnico: Software

Informações de Rotulagem

Labeling Scientific Library

Fonte: Journal of Clinical Medicine
DOI: 10.3390/jcm12185876

Gonzalez-Hernandez, M.; Betancor-Caro, N.; Mesa-Lugo, F.; Rodriguez-Talavera, I.; Pareja-Rios, A.; Guedes-Guedes, I.; Estevez-Jorge, B.; Trujillo-Blanco, M.; Cordova-Villegas, R.; Espinoza-Gonzalez, J.; et al.

Ler publicação

Fonte: Journal of Personalized Medicine
DOI: 10.3390/jpm13071128

Nissen, T.P.H.; Nørgaard, T.L.; Schielke, K.C.; Vestergaard, P.; Nikontovic, A.; Dawidowicz, M.; Grauslund, J.; Vorum, H.; Aasbjerg, K.

Ler publicação

Fonte: Journal of Clinical Medicine
DOI: 10.3390/jcm12175485

Mendez-Hernandez, C.; Gutierrez-Diaz, E.; Pazos, M.; Gimenez-Gomez, R.; Pinazo-Duran, M.D.

Ler publicação

Fonte: Journal of Clinical Medicine
DOI: 10.3390/jcm11247294

Gonzalez-Hernandez, M.; Gonzalez-Hernandez, D.; Betancor-Caro, N.; Guedes-Guedes, I.; Guldager, M.K.; Gonzalez de la Rosa, M.

Ler publicação

Fonte: BMJ Open Ophthalmology
DOI: 10.10136/bmjophth-2022-000972

Gonzalez- Hernandez M, Gonzalez- Hernandez D, Perez- Barbudo D, et al.

Ler publicação

Fonte: Journal of ophthalmology
DOI: 10.1155/2021/9916102

Rocha, J. A. G., Dias, D. T., Lemos, M. B. C., Kanadani, F. N., Paranhos, A., Jr, Gracitelli, C. P. B., & Prata, T. S. (2021).

Ler publicação

Fonte: Investigative Ophthalmology & Visual Science
Invest. Ophthalmol. Vis. Sci. 2021;62(8):72

Paloma Rodríguez-Esteve, Marta Gonzalez-Hernandez, Alicia Pareja-Rios, Manuel Gonzalez de la Rosa.

Ler publicação

Fonte: Investigative Ophthalmology & Visual Science
Invest. Ophthalmol. Vis. Sci. 2021;62(8):1828.

Marta Gonzalez-Hernandez, Daniel Gonzalez-Hernandez, Rodriguez-Esteve Paloma, Manuel Gonzalez-de-la-Rosa.

Ler publicação

Fonte: Investigative Ophthalmology & Visual Science
Invest. Ophthalmol. Vis. Sci. 2021;62(8):1009.

Manuel Gonzalez de la Rosa, Daniel Gonzalez-Hernandez, Marta Gonzalez-Hernandez, Daniel Perez-Barbudo.

Ler publicação

Fonte: Investigative Ophthalmology & Visual Science
Invest. Ophthalmol. Vis. Sci. 2021;62(8):1010

Nisamar Betancor Caro, Daniel Perez-Barbudo, Morten Kirk Guldager, Carmen Mendez-Hernandez, Marta Gonzalez-Hernandez

Ler publicação

Fonte: The British Journal of Ophthalmology
DOI: 10.1136/bjophthalmol-2020-316455

Mendez-Hernandez, C., Wang, S., Arribas-Pardo, P., Salazar-Quiñones, L., Güemes-Villahoz, N., Fernandez-Perez, C., & Garcia-Feijoo, J.

Ler publicação

Fonte: Journal of Clinical and Experimental Ophthalmology
DOI: 10.4172/2155-9570.1000760

Gonzalez-Hernandez D, Diaz-Aleman T, Perez-Barbudo D, Mendez-Hernandez C,de la Rosa MG, et al.

Ler publicação

Fonte: Journal of pediatric ophthalmology and strabismus
Invest. Ophthalmol. Vis. Sci. 2021;62(8):1010

Perucho-González, L., Méndez-Hernández, C. D., González-de-la-Rosa, M., Fernández-Pérez, C., Sáez-Francés, F., Andrés-Guerrero, V., & García-Feijoó, J.

Ler publicação

Fonte: 13th EGS Congresso em Florença

Marta Gonzalez-Hernandez, Silvia Alayon Miranda, Jose Sigut Saavedra, Manuel Gonzalez de la Rosa

Ler publicação

Fonte: Archivos de la Sociedad Espanola de Oftalmologia, 90(5), 212–219.
DOI: 10.1016/j.oftal.2014.09.007

Rodríguez Uña, I., Méndez Hernández, C. D., Sáenz-Francés, F., & García Feijóo, J.

Ler publicação

Fonte: Journal of Glaucoma
DOI: 10.1097/IJG.0000000000000160

Mendez-Hernandez, C., Garcia-Feijoo, J., Arribas-Pardo, P., Saenz-Frances, F., Rodriguez-Uña, I., Fernandez-Perez, C., & Gonzalez de la Rosa, M.

Ler publicação

Fonte: Investigative Ophthalmology & Visual Science
DOI: 10.1167/iovs.14-15592

Pena-Betancor C, GonzalezHernandez M, Fumero-Batista F, et al.

Ler publicação

Fonte: Investigative Ophthalmology & Visual Science
DOI: 10.1167/iovs.12-10761

Gonzalez de la Rosa, M., Gonzalez-Hernandez, M., Sigut, J., Alayon, S., Radcliffe, N., Mendez-Hernandez, C., García-Feijoo, J., Fuertes-Lazaro, I., Perez-Olivan, S., & Ferreras, A.

Ler publicação

Fonte: Glaucoma, Hospital Clinico San Carlos, Madrid, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

Carmen Mendez-Hernandez, Lucia Perucho, Julian Garcia Feijoo, Manuel Gonzalez de la Rosa

Ler publicação

Fonte: Current Eye Research
DOI: 10.3109/02713683.2015.1062112

Erica Medina-Mesa, Marta Gonzalez-Hernandez, Jose Sigut, Francisco Fumero-Batista, Cristina Pena-Betancor, Silvia Alayon & Manuel Gonzalez de la Rosa

Ler publicação

Fonte: Acta Ophthalmologica
DOI: 10.1111/aos.13050

Mendez-Hernandez, C., Rodriguez-Uña, I., Gonzalez-de-la Rosa, M., Arribas-Pardo, P., & Garcia-Feijoo, J.

Ler publicação

Fonte: Acta ophthalmologica Scandinavica
DOI: 10.1111/j.1600-0420.2004.00350.x

Hansen, A. B., Hartvig, N. V., Jensen, M. S., Borch-Johnsen, K., Lund-Andersen, H., & Larsen, M.

Ler publicação

Fonte: Diabetes Technology & Therapeutics
DOI: 10.1089/dia.2007.0239

Bouhaimed, M., Gibbins, R., & Owens, D.

Ler publicação

Fonte: Investigative Ophthalmology & Visual Science
DOI: 10.1167/iovs.02-0417

Larsen, N., Godt, J., Grunkin, M., Lund-Andersen, H., & Larsen, M.

Ler publicação

Fonte: Investigative Ophthalmology & Visual Science
DOI: 10.1167/iovs.02-0418

Larsen, M., Godt, J., Larsen, N., Lund-Andersen, H., Sjølie, A. K., Agardh, E., Kalm, H., Grunkin, M., & Owens, D. R.

Ler publicação

Fonte: The Danish Committee for Health Education

Michael Nyhus Andreasen, Jacob Kjellberg

Ler publicação

Fonte: Current Eye Research
DOI: 10.1080/02713680701215587

Larsen, M., Gondolf, T., Godt, J., Jensen, M. S., Hartvig, N. V., Lund-Andersen, H., & Larsen, N.

Ler publicação